ArticleNature communications2025
MIDAS: rapid, multiplexed molecular profiling for integrated host-pathogen analysis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor extracellular vesicle RNA profiling predicts treatment response in pediatric diffuse midline glioma.bioRxiv : the preprint server for biology · 2026Article
- MIDAS: rapid, multiplexed molecular profiling for integrated host-pathogen analysis.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Addressing the need for integrated molecular analysis in complex infectious conditions requires technologies that rapidly quantify both pathogens and host responses. This is particularly relevant in sepsis research, where existing tools typically measure either microbial or host biomarkers. Here, we present MIDAS (Multiplexed Intelligent Diffraction Analysis System), a proof-of-concept platform that integrates shape-encoded hydrogel particles with lens-free diffraction imaging and deep learning-based analysis to enable simultaneous quantification of bacterial RNA and inflammatory proteins in a single system optimized for potential point-of-care use. The assay completes multiplexed measurements in under 4 h, significantly faster than standard culture workflows ( ~ 20-40 h). Beyond spiked studies, MIDAS is evaluated using specimens from a clinically relevant porcine sepsis model, showing high concordance with culture, qPCR and ELISA. Although further clinical validation is required, this flexible platform may support the development of accessible host-pathogen profiling tools with broad applications in healthcare, agriculture, food safety, and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.